Novartis is currently involved in a multi-district patent litigation campaign to block generic entrants for its blockbuster heart medication. On July 7, the district court invalidated the patent for lack of written description despite rejecting an enablement defense based upon the same evidence.
In its turn, on September 17th, Senior Party ToolGen Inc. filed its Motion to Exclude certain evidence presented by Junior Party the University of California/Berkeley, the University of.